
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Short Communication |
Departments of Medicine [Y-I. K.] and Nutritional Sciences [Y-I. K.], Division of Gastroenterology, University of Toronto and St. Michaels Hospital, Toronto, Ontario, M5S 1A8 Canada; Divisions of Clinical Nutrition [J. B. M.] and Gastroenterology [K. F., T. K., Y-M. L., R. N., E. L., J. B. M.], Department of Internal Medicine, New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts; and Vitamin Metabolism Laboratory, Jean Mayer United States Department of Agriculture Human Nutrition Research Center on Aging at Tufts University, Boston, Massachusetts 02111 [J. B. M.]
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
Whether blood concentrations of folate accurately reflect concentrations in the colonic mucosa has been a controversial topic. Studies in which rodents were fed different dietary amounts of folate have shown that colonic mucosal folate concentrations are significantly correlated with dietary intake and blood folate concentrations (6 , 7) . In one human study (n = 30; Ref. 5 ), colonic mucosal folate concentrations measured in endoscopic biopsy samples correlated directly with serum and RBC folate concentrations (r = 0.62; P < 0.001; and r = 0.46; P = 0.013, respectively) and inversely with serum homocysteine (r = -0.72; P < 0.001), a sensitive, inverse, systemic measure of cellular folate depletion (4) . In contrast, two other human studies (n = 2227) demonstrated no significant correlations between folate concentrations in isolated colonic epithelial cells and serum and RBC folate measurements (8 , 9) . Thus, there exists a concern that systemic folate indices might not accurately reflect folate concentrations in the colorectal mucosa.
This study investigated whether conventional blood (serum and RBC) measurements of folate and serum homocysteine levels accurately reflect folate concentrations in the colonic mucosa obtained from endoscopic biopsy in subjects who were participants in a randomized trial that investigated the effect of folate supplementation (5 mg daily) on molecular markers in the colon (10) . Some of the data from the baseline state were previously reported by us (5) . However, the present study adds a very important perspective to our previous observations, because it followed subjects prospectively over time, and because the inclusion of subjects receiving folate supplementation enabled us to examine whether such correlations continued to exist under conditions where subjects were receiving supraphysiological levels of folate.
| Materials and Methods |
|---|
|
|
|---|
Twenty subjects over 18 years of age with histologically confirmed colonic adenomas were randomized to receive either 5 mg folate/day (n = 9) or placebo (n = 11) for 1 year subsequent to polypectomy after satisfying the specific inclusion and exclusion criteria as published previously (10) . At baseline, clinical and laboratory characteristics were not significantly different between the two groups. All subjects underwent colonoscopy at baseline and at 1 year and sigmoidoscopy at 6 months. All patients were prepared for colonoscopy by colonic lavage solution (GoLYTELY; Braintree Laboratories, Inc., Braintree, MA) administered p.o. Colonoscopy was performed in the standard fashion, and all identifiable polyps were removed and processed for routine histology.
At the time of each colonoscopic and sigmoidoscopic examination, three biopsies of normal-appearing mucosa at the rectosigmoid junction (15 cm from the anal verge as measured by the distance of the scope inserted into the colon), at least 5 cm away from any polyp or other mucosal abnormality, were performed with standard biopsy forceps. These biopsies were immediately placed in a foil packet, immersed in liquid nitrogen, and then stored at -70°C for subsequent analysis of colonic mucosal folate concentrations. After colonoscopy was completed, venous blood was drawn from each subject (in a fasting state) for measurement of serum and RBC folate and serum homocysteine concentrations. Blood for measuring serum folate and homocysteine concentrations was collected into vacuum blood collection tubes and centrifuged at 800 x g for 10 min at 4°C, and serum was stored at -70°C until assayed. The aliquot of serum for the folate analysis was stored in 0.5% sodium ascorbate, which is known to retard folate degradation in storage (11) . An aliquot of whole blood, used to measure the RBC folate concentration, was stored in 1% ascorbic acid at -70°C for the same reason.
All assays for serum and RBC folate and serum homocysteine were performed within 2 months of collection. Colonic mucosal folate was extracted from three rectosigmoid mucosal biopsy samples within 1 week of collection and stored at -70°C, and its concentration was determined within 2 months of extraction. Previously, it has been shown that serum and RBC folate and extracted folate from tissues are stable for 12 months when stored at or below -20°C with ascorbic acid (11, 12, 13) .
RBC folate concentrations were determined by radioassay (MAGIC kit; Ciba-Corning Magnetic Immunochemistries, Medfield, MA). Serum folate was measured by a standard microbiological microtiter plate assay using Lactobacillus casei (13) . Colonic mucosal folate concentrations were also measured by the microbiological assay, using a previously described method for the determination of tissue folates (14) . Three rectosigmoid biopsies from each subject at each time point were combined for folate extraction. A rapid determination of biopsy weight was followed immediately by extraction of tissue folates in 20 volumes of freshly prepared folate extraction buffer [5 mM ß-mercaptoethanol and 0.1 M sodium ascorbate in 0.1 M bis(2-hydroxyethyl)imino-tris(hydroxymethyl) methane (pH 7.85)] at 95°C for 20 min. It has been shown previously that more than 95% of tissue folates can be extracted using this technique (15, 16, 17) . Extracts were then treated with chicken pancreas conjugase to convert all of the folylpolyglutamates to their corresponding diglutamate derivatives (18) , thereby enabling the extracts to be subjected to the microbiological assay. Prior studies have shown that a single treatment of tissue folates with chicken pancrease conjugase is sufficient to convert all of the folylpolyglutamates to diglutamates (13 , 19) Total serum homocysteine was measured by high-performance liquid chromatography according to the fluorometric method of Vester and Rasmussen (20) . All laboratory assays were performed in a blinded fashion.
Blinded replicate quality-control phantom samples from male volunteers aged 5069 years were placed toward the beginning and the end of each bath. Intra-assay coefficients of variation for folate and homocysteine were 10 and 5%, respectively. Inter-assay coefficients of variation for folate and homocysteine were 11 and 3%, respectively. Previously published studies are associated with the coefficient of variation for this folate assay of
11% (11, 12, 13)
.
All variables were determined to be normally distributed by a graphic analysis. Linear regression was used to assess the correlation between variables. All significance tests were two-sided and were considered to be statistically significant if the observed significance level (P) was <0.05. Statistical analyses were performed by using SYSTAT 5 for Macintosh (Systat, Evanston, IL).
| Results |
|---|
|
|
|---|
As shown in Table 1
, colonic mucosal concentrations of folate correlated directly with serum folate concentrations at each time point (r = 0.5720.845; P < 0.015). Colonic mucosal concentrations of folate correlated directly with RBC folate concentrations at 6 months and at 1 year (r = 0.7470.771; P < 0.001) but not at baseline (Table 1)
. Serum homocysteine concentrations correlated inversely with colonic mucosal folate concentrations at each time point (r = -0.6220.666; P < 0.008; Table 1
). Fig. 1
demonstrates all values of serum and RBC folate and serum homocysteine concentrations from the three time points plotted against colonic mucosal folate concentrations.
|
|
|
| Discussion |
|---|
|
|
|---|
A novel finding from this present study is that, although serum and RBC folate concentrations in conventional physiological ranges correlate well with colonic mucosal folate concentrations, these measurements in supraphysiological ranges resulting from folate supplementation (12.5 times higher than the required daily allowance) did not correlate significantly with colonic mucosal folate concentrations. This observation is probably related to the fact that folate accumulation in tissues is limited by the level of FPGS3
activity in the setting of substrate excess (22
, 23)
. FPGS catalyzes polyglutamation of cellular folates, thereby allowing the retention of folate that would otherwise be lost because of efflux from the cell (22
, 23)
. Previous studies in animals and in cultured cells have shown that tissue levels of folate reach a plateau when FPGS is saturated from excess folate in the diet or culture medium (6
, 22
, 24)
. Although the tissue "saturating" blood levels of folate have not yet been determined in humans, a previous animal study has shown that the saturation levels of colonic mucosal folate were reached when serum folate concentrations exceeded
90 ng/ml (6)
. A visual inspection of Fig. 1
suggests that serum values exceeding
100 ng/ml or RBC values exceeding
800 ng/ml are unlikely to be accurate reflections of colonic folate concentrations. These thresholds are only exceeded when individuals are consuming supraphysiological doses of folate. Taken together, these data therefore suggest that serum and RBC concentrations of folate in supraphysiological ranges may not accurately predict the actual colonic mucosal folate concentrations.
Although serum homocysteine concentrations were the best indicator of colonic mucosal folate concentrations in a previous human study (5) , the association between serum homocysteine levels and colonic mucosal folate concentration was weaker than those among serum, RBC, and colonic mucosal folate concentrations in the present study. A significant inverse association between serum homocysteine and colonic mucosal folate concentrations was observed at baseline and when values from subjects on placebo and those receiving folate supplementation were combined at 6 months and 1 year. However, no significant inverse association between these two parameters was observed at 6 months and 1 year when subjects not receiving folate and subjects receiving folate supplementation were separately analyzed. In the parent study (10) from which the present study was derived, serum homocysteine concentrations significantly increased at 6 months and 1 year, for unknown reasons, compared with the baseline values in both the placebo and folate-supplemented groups. This was an unusual finding, given that folate supplementation significantly increased serum (by 2.74.4 times), RBC (by 1.92.0 times), and colonic mucosal (by 2.23.6 times) folate concentrations from the baseline values at 6 months and 1 year, whereas serum, RBC and colonic mucosal folate concentrations did not significantly change over time in the placebo group (10) . Therefore, it is possible that factors other than folate might have contributed to this abnormal response in serum homocysteine levels during the study period, which in turn might have affected correlations between serum homocysteine and colonic mucosal folate concentrations. It is well known that a strong, nonlinear, inverse association exists between plasma homocysteine and folate concentrations; in the upper ranges of plasma folate concentrations, however, plasma homocysteine levels are less affected by plasma folate concentrations (25 , 26) . This may be the case for the inverse association between serum homocysteine levels and colonic mucosal folate concentrations. Future studies are warranted to better define the relationship between colonic mucosal folate and serum homocysteine levels in both physiological and supraphysiological ranges of serum and RBC folate concentrations.
One potential limitation of the present study is the relatively small number of subjects (n = 20 at baseline). This number was reduced further when those not receiving folate and those receiving folate supplementation were separately analyzed at the two follow-up time points. Despite the small sample size, however, we found significant direct correlations between blood measurements of folate and colonic mucosal folate concentrations, and inverse correlations between serum homocysteine and colonic mucosal folate concentrations. The small sample size probably accounts for the lack of consistent correlations between RBC and colonic mucosal folate concentrations (at baseline) and between serum homocysteine and colonic mucosal folate concentrations (when those not receiving folate and those receiving folate supplementation were separately analyzed at 6 months and at 1 year).
At present it is uncertain what constitutes a normal range of folate concentrations in the colonic mucosa, and what is the threshold of colonic mucosal folate concentrations below which colorectal cancer risk increases. These issues need to be resolved, because accurate measures of folate status in the colorectal mucosa are important for identifying target groups of individuals at increased risk of developing colorectal cancer for aggressive screening and for potential folate chemoprevention. Our present data, in conjunction with previous studies (5, 6, 7) , suggest that serum and RBC folate concentrations in conventional physiological ranges are good indicators of colonic mucosal concentrations. These blood measurements of folate may be used (with some misclassification error) to classify patients into those with low, normal, and high colonic mucosal levels of folate. However, it appears that, once supplementation is initiated, the ability of serum and RBC folate concentrations in supraphysiological ranges to accurately predict colonic mucosal folate concentrations is less reliable.
| Acknowledgments |
|---|
| Footnotes |
|---|
1 Supported in part by the National Cancer Institute Grants 1-UO1 CA63812-01 and RO1 CA59005-05S1 (to J. B. M.), the American Gastroenterological Association/Smith Kline Beecham Award for Clinical Research (to J. B. M.), a Research Fellowship and Scholarship from the Medical Research Council of Canada (to Y-I. K.), and Agreement 58-1950-9-001 from the U. S. Department of Agriculture, Agricultural Research Service (to J. B. M.). Support was also provided through the General Clinical Research Center, funded by the NIH MO1 RR00054 from the Division of Research Resources and P30 DK34928GRASP from the Digestive Disease Center, National Institute of Diabetes and Digestive and Kidney Diseases. ![]()
2 To whom requests for reprints should be addressed, at Room 7258, Medical Sciences Building, University of Toronto, 1 Kings College Circle, Toronto, Ontario, M5S 1A8 Canada. Phone: (416) 978-1183; Fax: (416) 978-8765; E-mail: youngin.kim{at}utoronto.ca ![]()
3 The abbreviation used is: FPGS, folylpolyglutamate synthetase. ![]()
Received 11/ 2/00; revised 3/14/01; accepted 4/ 4/01.
| References |
|---|
|
|
|---|
-glutamate synthetase in therapeutics with tetrahydrofolate antimetabolites: an overview. Semin. Oncol., 26: 24-32, 1999.[Medline]
-glutamate synthetase substrate specificity and level on folate metabolism and folylpoly-
-glutamate specificity of metabolic cycles of one-carbon metabolism. J. Biol. Chem., 268: 21665-21673, 1993.This article has been cited by other articles:
![]() |
J. C. Figueiredo, A. J. Levine, M. V. Grau, E. L. Barry, P. M. Ueland, D. J. Ahnen, T. Byers, R. S. Bresalier, R. W. Summers, J. Bond, et al. Colorectal Adenomas in a Randomized Folate Trial: The Role of Baseline Dietary and Circulating Folate Levels Cancer Epidemiol. Biomarkers Prev., October 1, 2008; 17(10): 2625 - 2631. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. J. Powers, M. H. Hill, M. Welfare, A. Spiers, W. Bal, J. Russell, Y. Duckworth, E. Gibney, E. A. Williams, and J. C. Mathers Responses of Biomarkers of Folate and Riboflavin Status to Folate and Riboflavin Supplementation in Healthy and Colorectal Polyp Patients (The FAB2 Study) Cancer Epidemiol. Biomarkers Prev., October 1, 2007; 16(10): 2128 - 2135. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kawakami, A. Ruszkiewicz, G. Bennett, J. Moore, G. Watanabe, and B. Iacopetta The Folate Pool in Colorectal Cancers Is Associated with DNA Hypermethylation and with a Polymorphism in Methylenetetrahydrofolate Reductase Clin. Cancer Res., December 1, 2003; 9(16): 5860 - 5865. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Odin, Y. Wettergren, S. Nilsson, R. Willen, G. Carlsson, C. P. Spears, L. Larsson, and B. Gustavsson Altered Gene Expression of Folate Enzymes in Adjacent Mucosa Is Associated with Outcome of Colorectal Cancer Patients Clin. Cancer Res., December 1, 2003; 9(16): 6012 - 6019. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Little, L. Sharp, S. Duthie, and S. Narayanan Colon Cancer and Genetic Variation in Folate Metabolism: The Clinical Bottom Line J. Nutr., November 1, 2003; 133(11): 3758S - 3766. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. D. Davis Use of Exfoliated Cells from Target Tissues to Predict Responses to Bioactive Food Components J. Nutr., June 1, 2003; 133(6): 1769 - 1772. [Abstract] [Full Text] [PDF] |
||||
![]() |
K.-J. Sohn, J. M. Stempak, S. Reid, S. Shirwadkar, J. B. Mason, and Y.-I. Kim The effect of dietary folate on genomic and p53-specific DNA methylation in rat colon Carcinogenesis, January 1, 2003; 24(1): 81 - 90. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |